Matches in SemOpenAlex for { <https://semopenalex.org/work/W2174920275> ?p ?o ?g. }
Showing items 1 to 54 of
54
with 100 items per page.
- W2174920275 abstract "Introduction Heavy menstrual bleeding (HMB) commonly affects 1.5 million women in the UK, thereby prompting 1 in 20 women of reproductive age to seek treatment to improve their quality of life. The NICE guidelines recommend the use of Mirena in treating benign HMB, followed by endometrial destruction, if medical treatments fail to resolve symptoms. Several studies have shown the efficacy and cost-effectiveness of using Mirena, endometrial ablation and hysterectomy individually, but evidence on the efficacy of combining endometrial ablation and Mirena compared with other treatments remains inadequate. The objective of this study was to evaluate the efficacy and outcomes of women with HMB via combined use of Thermachoice ablation and Mirena. Methods Forty-nine patients with persistent HMB following initial treatment involving either Mirena, Thermachoice ablation or medical treatments were randomly selected from the sample population between 2005 to 2011 and consented to have combined Thermachoice ablation and Mirena. Our primary outcome measures were satisfaction levels 6 months post-treatment, amenorrhoea rates and rates of subsequent hysterectomy. Results There were similar number of patients in the each age group, including aged 35 to 40 (15 patients), 41 to 45 (17 patients) and 46 to 50 (15 patients), except for 2 patients aged beyond 50. 33 of 49 patients had at least two live births and BMI of above 30 respectively. 36 (73%) patients had normal pelvic scan findings, 10 patients had abnormal findings and subsequent histology specimen excluded hyperplasia, atypia and malignancy, and 3 patients had inconclusive findings due to high BMI. Out of 49 patients, 18 (37%) had Mirena, 2 (4%) had Thermachoice ablation and 29 (59%) had medical treatments after declining Mirena initially. Following initial treatment, 16 patients with Mirena and all patients who had ablation and medical treatments (96%) developed initial spotting that persisted to severe loss. Following subsequent counselling and combined treatment of Thermachoice ablation and Mirena, 38 (78%) patients were very satisfied with their symptoms (3 of 3 satisfaction ratings), 36 (73%) patients had high amenorrhoea rates and only 11 (22%) patients had persistent spotting that led to a hysterectomy. No other serious complications occurred in these patients following subsequent treatment. Conclusion The combined use of Thermachoice ablation and Mirena in treating HMB remains justified based on the overall outcomes and a large prospective study is required to compare its efficacy with other treatments. References 1. Vaughan D, Byrne P. J Obstet Gynaecol 2012 May; 32(4): 372-4." @default.
- W2174920275 created "2016-06-24" @default.
- W2174920275 creator A5015788001 @default.
- W2174920275 creator A5021713830 @default.
- W2174920275 creator A5085935298 @default.
- W2174920275 date "2014-01-01" @default.
- W2174920275 modified "2023-09-26" @default.
- W2174920275 title "The Combined Use Of Thermachoice Ablation And Mirena In The Management Of Heavy Menstrual Bleeding" @default.
- W2174920275 doi "https://doi.org/10.5339/qfarc.2014.hbpp0411" @default.
- W2174920275 hasPublicationYear "2014" @default.
- W2174920275 type Work @default.
- W2174920275 sameAs 2174920275 @default.
- W2174920275 citedByCount "0" @default.
- W2174920275 crossrefType "proceedings-article" @default.
- W2174920275 hasAuthorship W2174920275A5015788001 @default.
- W2174920275 hasAuthorship W2174920275A5021713830 @default.
- W2174920275 hasAuthorship W2174920275A5085935298 @default.
- W2174920275 hasConcept C126322002 @default.
- W2174920275 hasConcept C131872663 @default.
- W2174920275 hasConcept C141071460 @default.
- W2174920275 hasConcept C2777687323 @default.
- W2174920275 hasConcept C2777689261 @default.
- W2174920275 hasConcept C2778937548 @default.
- W2174920275 hasConcept C2779076696 @default.
- W2174920275 hasConcept C2779494336 @default.
- W2174920275 hasConcept C2779742232 @default.
- W2174920275 hasConcept C2779771394 @default.
- W2174920275 hasConcept C2908647359 @default.
- W2174920275 hasConcept C29456083 @default.
- W2174920275 hasConcept C2986817661 @default.
- W2174920275 hasConcept C71924100 @default.
- W2174920275 hasConcept C99454951 @default.
- W2174920275 hasConceptScore W2174920275C126322002 @default.
- W2174920275 hasConceptScore W2174920275C131872663 @default.
- W2174920275 hasConceptScore W2174920275C141071460 @default.
- W2174920275 hasConceptScore W2174920275C2777687323 @default.
- W2174920275 hasConceptScore W2174920275C2777689261 @default.
- W2174920275 hasConceptScore W2174920275C2778937548 @default.
- W2174920275 hasConceptScore W2174920275C2779076696 @default.
- W2174920275 hasConceptScore W2174920275C2779494336 @default.
- W2174920275 hasConceptScore W2174920275C2779742232 @default.
- W2174920275 hasConceptScore W2174920275C2779771394 @default.
- W2174920275 hasConceptScore W2174920275C2908647359 @default.
- W2174920275 hasConceptScore W2174920275C29456083 @default.
- W2174920275 hasConceptScore W2174920275C2986817661 @default.
- W2174920275 hasConceptScore W2174920275C71924100 @default.
- W2174920275 hasConceptScore W2174920275C99454951 @default.
- W2174920275 hasLocation W21749202751 @default.
- W2174920275 hasOpenAccess W2174920275 @default.
- W2174920275 hasPrimaryLocation W21749202751 @default.
- W2174920275 isParatext "false" @default.
- W2174920275 isRetracted "false" @default.
- W2174920275 magId "2174920275" @default.
- W2174920275 workType "article" @default.